Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Raza, A; Fenaux, P; Erba, H; Mandelli, F; Schiller, G; Larson, R; Denzlinger, C; Greenberg, P; Muus, P; Gotlib, J; Bennett, J; Leopold, L; Lejeune, C; Richie, M; Berger, M

Published Date

  • November 16, 2002

Published In

Volume / Issue

  • 100 / 11

Start / End Page

  • 795A - 795A

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 44th Annual Meeting of the American-Society-of-Hematology

Conference Location

  • PHILADELPHIA, PENNSYLVANIA

Conference Start Date

  • December 6, 2002

Conference End Date

  • December 10, 2002